Immediate Impact

2 by Nobel laureates 3 from Science/Nature 75 standout
Sub-graph 1 of 23

Citing Papers

Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
2025 Standout
From geroscience to precision geromedicine: Understanding and managing aging
2025 Standout
2 intermediate papers

Works of Fred Yang being referenced

Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise
2015
HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin
2014

Author Peers

Author Last Decade Papers Cites
Fred Yang 379 751 162 296 15 840
Susan Johnson 362 718 171 294 25 952
Steen H. Ingwersen 351 605 110 227 30 852
Charles Atisso 454 789 238 251 17 834
Lene Jensen 450 702 152 325 10 819
Amanda Mather 267 492 77 262 22 786
Zin Zin Htike 350 764 177 269 14 877
George Tsoukas 292 555 141 170 14 654
Nelun Wijayasinghe 310 493 152 225 12 710
Michaël J.B. van Baar 226 623 107 298 11 728
Mario Widel 422 749 135 272 7 901

All Works

Loading papers...

Rankless by CCL
2026